Skip to main content

Many people diagnosed with hypertension in four of the world’s biggest middle-income countries have stopped treatment, and most of these patients have lost control of blood pressure – potentially leading to heart problems and death, a new study reveals.

The researchers analyzed patient data from China, Indonesia, Mexico, and South Africa. They found that policies solely aimed at improving diagnosis or initiating treatment may not lead to long-term hypertension control improvements in these and similar countries.

Researchers investigating how people with hypertension move through care over time looked at adults aged 40 and over. They discovered that over a 5- to 9-year follow-up period, only around 30% of undiagnosed individuals became diagnosed, whilst 25% of untreated individuals became treated.

Key findings on hypertension

The most striking finding, however, was that among those that were on treatment and had controlled blood pressure, the majority lost blood pressure control. In addition, a substantial number stopped treatment over the 5- to -9-year period.

An international group of researchers published their findings in Science Translational Medicine. The group includes the University of Birmingham and the Technical University of Munich.

These were the observations by country.

South Africa

  • South Africa had the lowest rates of undiagnosed hypertension, treatment discontinuation and blood pressure control loss, as well as the highest probabilities of individuals reaching blood pressure control.

Hypertension| Longevity LiveChina

  • China had one of the lowest rates of reaching blood pressure control, with just 9% of individuals likely to achieve this – regardless of treatment status.
  • In Indonesia, 92% of individuals lost blood pressure control at follow-up, with the country also displaying the highest treatment discontinuation and lowest treatment initiation rates – suggesting substantial barriers in accessing and following up care.

Mexico

  • In Mexico, only 27% of people were likely to be diagnosed with hypertension. On the other hand, 34% of individuals with a diagnosis later discontinued their treatment.

One in four adults worldwide will be affected by hypertension

According to Professor Justine Davies from the University of Birmingham, “Hypertension affects one in four adults and is the world’s leading cause of cardiovascular disease and early death.”

“Two-thirds of people with hypertension live in low- and middle-income countries, and these countries in particular face considerable population ageing, which is likely to generate a surge in people requiring hypertension care. Treating hypertension substantially reduces deaths from cardiovascular disease mortality, yet many countries have crucial gaps in hypertension diagnosis and control.”

Sadly, only 21 MICs out of 106 classified by the World Bank are on track to achieve the Sustainable Development Goal target. The target is 3.4 to reduce premature mortality from noncommunicable diseases (NCDs) by one-third by 2030.

Nikkil Sudharsanan, Assistant Professor of Behavioral Science for Disease Prevention and Health Care at the Technical University of Munich, also weighed in on the research findings.

“Our analysis covered four large middle-income countries making up close to a quarter of the world’s population. We found that diagnosis and treatment initiation are major bottlenecks to achieving blood pressure control.

Nonetheless, treatment discontinuation and loss of blood pressure control are equally problematic and reveal that we can’t expect long-term hypertension control from interventions that seek to improve diagnosis and treatment initiation without efforts to also keep people in care and their blood pressure controlled over time.”

References

  • The University of Birmingham is ranked amongst the world’s top 100 institutions. Its work brings people from across the world to Birmingham. This includes researchers, teachers, and more than 6,500 international students from over 150 countries.
  • ‘Treatment discontinuation, adherence, and loss of 1 hypertension control. Longitudinal evidence from four middle-income countries’ – Nicole Mauer, Pascal Geldsetzer, Jennifer Manne-Goehler, Justine I. Davies, Andrew C. Stokes, Margaret McConnell, Mohammed K. Ali, Volker Winkler and Nikkil Sudharsanan is published in Science Translational Medicine.
  • Participating institutions include:
    • University of Birmingham
    • Technical University of Munich, Germany
    • Heidelberg University, Germany
    • Stanford University, USA
    • Chan Zuckerberg Biohub, San Francisco, USA
    • Harvard T.H. Chan School of Public Health, Boston, USA
    • University of Witwatersrand, Johannesburg, South Africa
    • Boston University, USA
    • Emory University, Atlanta, USA
    • University of Munich, Germany
    • European Observatory on Health Systems and Policies, Brussels, Belgium
Em Sloane

Em Sloane

I am an introverted nature lover, and long time contributor to LongevityLive.com. My role is to publish the information in a consumer friendly format, which we receive on the latest medical news, press releases and general information on the latest longevity related research findings.

Longevity Live is a digital publisher AND DOES NOT OFFER PERSONAL HEALTH OR MEDICAL ADVICE. IF YOU’RE FACING A MEDICAL EMERGENCY, CALL YOUR LOCAL EMERGENCY SERVICES IMMEDIATELY, OR VISIT THE NEAREST EMERGENCY ROOM OR URGENT CARE CENTER. YOU SHOULD CONSULT YOUR HEALTHCARE PROVIDER BEFORE STARTING ANY NUTRITION, DIET, EXERCISE, FITNESS, MEDICAL, OR WELLNESS PROGRAM.

This content, developed through collaboration with licensed medical professionals and external contributors, including text, graphics, images, and other material contained on the website, apps, newsletter, and products (“Content”), is general in nature and for informational purposes only and does not constitute medical advice; the Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Always consult your doctor or other qualified healthcare provider with any questions you may have regarding a medical condition, procedure, or treatment, whether it is a prescription medication, over-the-counter drug, vitamin, supplement, or herbal alternative.

Longevity Live makes no guarantees about the efficacy or safety of products or treatments described in any of our posts. Any information on supplements, related services and drug information contained in our posts are subject to change and are not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects.

Longevity does not recommend or endorse any specific test, clinician, clinical care provider, product, procedure, opinion, service, or other information that may be mentioned on Longevity’s websites, apps, and Content.